Synuclein-One Study

CND Life Sciences428 enrolled

Overview

The Synuclein-One Study will be evaluating α-synuclein in patients with Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies and Pure Autonomic Failure. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguish between neurodegenerative diseases.

Phosphorylated α-synuclein pathology in the diagnosis of synucleinopathies through qualitative and quantitative measurements of cutaneous phosphorylated α-synuclein in patients with Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies and Pure Autonomic Failure. An effective tissue biomarker will provide an accurate diagnosis of α-synuclein in clinical practice, will differentiate between synucleinopathies, enable assessment of target engagement in the development of disease modifying and neuroprotective therapies and accelerate the development of neuroprotective and disease modifying therapies.

Study Type

OBSERVATIONAL

Enrollment

428

Conditions

Parkinson Disease Multiple System Atrophy Dementia With Lewy Bodies Pure Autonomic Failure

Interventions

Skin BiopsyDIAGNOSTIC_TEST

Test accuracy and precision of skin biopsy detection of phosphorylated α-synuclein, define sensitivity and specificity of skin biopsy detection of phosphorylated α-synuclein deposition for the diagnosis of synucleinopathies and to differentiate between the synucleinopathies by quantitative measurement of phosphorylated α-synuclein with skin biopsies.

Eligibility

Sex: ALLMin age: 40 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male and female between 40-99 years of age * Prior clinical diagnosis of Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies or Pure Autonomic Failure * Health Subjects, no history of clinical or symptoms suggestive with synucleinopathy Exclusion Criteria: * Clinical evidence of severe vascular disease (history of ulceration, poor wound healing, vascular claudication) * Clinically active coronary artery or cerebrovascular disease * Current smoker or alcoholism * History of allergic reaction to local anesthesia for skin biopsies * Use of blood thinners (aspirin or Plavix alone is allowed) * Significantly impaired wound healing or history of scarring or keloid formation * Healthy individuals or individuals with synucleinopathy is disease may be explained by other causes: recent history of encephalitis, Cortical dementia of Alzheimer's type, Whipple's disease, toxin exposure, repeated head injury and stepwise disease progression suggestive of vascular etiology

Locations (23)

MD First Research

Chandler, Arizona, United States

Outcomes

Primary Outcomes

Primary Outcome 1

To define test accuracy and precision of skin biopsy detection of phosphorylated α-synuclein.

Time frame: 2 years

Primary Outcome 2

To define sensitivity and specificity of skin biopsy detection of phosphorylated α-synuclein.

Time frame: 2 years

Primary Outcome 3

To differentiate between the synucleinopathies by quantitative measurement of phosphorylated α-synuclein with skin biopsies.

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.